Ameriprise’s Moderna MRNA Stock Holding History

Ameriprise’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-383,900	Closed	-$9.92M	–	4169
2025 Q3	$9.92M	Buy	+383,900	New	+$10.7M	﹤0.01%	1917

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Ameriprise's MRNA Position: Q2 2026 in Review

Ameriprise reduced its Moderna (MRNA) stake by 3.3% in Q2 2026, selling an estimated $244K and leaving 138,731 shares worth $9.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2077.

Ameriprise first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $93.2M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Ameriprise held 138,731 shares of Moderna worth $9.72M as of Q2 2026.
Ameriprise sold 4,718 Moderna shares in Q2 2026, an estimated $244K.
Moderna made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2077 holding.
Ameriprise first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
Ameriprise's Moderna position peaked at $93.2M in Q3 2021.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.